NCT05829226 - A Phase 1 Study With LYT-200 in Patients With Relapsed/Refractory Acute Myeloid Leukemia (AML), or With Relapsed/Refractory, High-risk Myelodysplastic Syndrome (MDS) | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

December 12, 2022

Primary Completion Date

December 31, 2025

Study Completion Date

March 31, 2026

Conditions

AML, Adult RecurrentMDS

Interventions

DRUG

LYT-200

monoclonal antibody (mAb), targeting galectin-9 protein

DRUG

Venetoclax

Bcl-2 inhibitor

DRUG

Azacitidine

Hypomethylating agent

DRUG

Decitabine

Hypomethylating agent

Trial Locations (9)

23219

RECRUITING

Virginia Commonwealth University Medical Center, Richmond

40207

RECRUITING

Norton Healthcare-Norton Cancer Institute, Louisville

48201

RECRUITING

Karmanos Cancer Institute, Detroit

90048

RECRUITING

Cedars-Sinai Medical Center, Los Angeles

92868

RECRUITING

University of California Irvine Medical Center, Orange

02114

RECRUITING

Baptist Health South Florida-Miami Cancer Institute, Miami

RECRUITING

Mass. General Hospital-Harvard, Boston

08901

RECRUITING

Rutgers Cancer Institute of New Jersey, New Brunswick

02903

RECRUITING

Rhode Island Hospital, Providence

All Listed Sponsors

lead

PureTech

INDUSTRY